Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT5B | P51692 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096028 | 0.89 | STAT5B (0.80) | STAT5BTP53LMNAGAAMAPT | |
| SCHEMBL22096018 | 0.86 | STAT5B (0.75) | STAT5BLMNAGAATSHRALDH1A1 | |
| SCHEMBL11888589 | 0.85 | STAT5B (1.00) | STAT5BTP53GAAMAPTALDH1A1 | |
| SCHEMBL22096009 | 0.85 | STAT5B (0.73) | STAT5BTP53LMNAGAAMAPT | |
| SCHEMBL20047794 | 0.85 | STAT5B (0.74) | STAT5BTP53LMNAGAAMAPT | |
| SCHEMBL20041699 | 0.82 | STAT5B (0.70) | STAT5BTP53LMNAGAAMAPT | |
| SCHEMBL22096027 | 0.80 | STAT5B (0.66) | STAT5BTP53LMNAGAAMAPT | |
| SCHEMBL22096017 | 0.72 | STAT5B (0.65) | STAT5BTSHRALDH1A1HPGD | |
| SCHEMBL22096019 | 0.68 | STAT5B (0.62) | STAT5BMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL22096025 | 0.67 | STAT5B (0.67) | STAT5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523297-B1 | NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER | UNIV BERLIN FREIE (DE) | 2021-07-07 | — | — | EP | disclosed |
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FREIE UNIVERSITAET BERLIN (DE) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FLT3, MCL1, MYD88 | STAT5B 59/4885TP53 4/4885LMNA 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.